These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
536 related articles for article (PubMed ID: 27627749)
41. OCULAR PERFUSION PRESSURE AND CHOROIDAL THICKNESS IN CENTRAL SEROUS CHORIORETINOPATHY AND PIGMENT EPITHELIOPATHY. Yun C; Han JY; Cho S; Hwang SY; Kim SW; Oh J Retina; 2019 Jan; 39(1):143-149. PubMed ID: 29095356 [TBL] [Abstract][Full Text] [Related]
42. INDOCYANINE GREEN ANGIOGRAPHY OF PACHYCHOROID PIGMENT EPITHELIOPATHY. Ersoz MG; Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M Retina; 2018 Sep; 38(9):1668-1674. PubMed ID: 28723851 [TBL] [Abstract][Full Text] [Related]
43. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599 [No Abstract] [Full Text] [Related]
44. EN FACE IMAGING OF PACHYCHOROID SPECTRUM DISORDERS WITH SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY. Dansingani KK; Balaratnasingam C; Naysan J; Freund KB Retina; 2016 Mar; 36(3):499-516. PubMed ID: 26335436 [TBL] [Abstract][Full Text] [Related]
45. Eplerenone for treatment of chronic central serous chorioretinopathy. Fraenkel D; Suffo S; Langenbucher A; Seitz B; Abdin AD Eur J Ophthalmol; 2021 Jul; 31(4):1885-1891. PubMed ID: 32854564 [TBL] [Abstract][Full Text] [Related]
46. Subthreshold Micropulse Laser Versus Oral Spironolactone in Chronic Central Serous Chorioretinopathy: A Quasi-Randomized Controlled Trial. Gao S; Ge G; Zhang Y; Zhang M Transl Vis Sci Technol; 2024 Aug; 13(8):19. PubMed ID: 39133498 [TBL] [Abstract][Full Text] [Related]
47. SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY. Ramos-Yau EC; Muñoz-Domínguez E; Contreras-Mérida SP; Valencia-Londoño LM Retin Cases Brief Rep; 2020; 14(4):381-385. PubMed ID: 29595560 [TBL] [Abstract][Full Text] [Related]
48. Choroidal vessel diameter in central serous chorioretinopathy. Yang L; Jonas JB; Wei W Acta Ophthalmol; 2013 Aug; 91(5):e358-62. PubMed ID: 23647989 [TBL] [Abstract][Full Text] [Related]
49. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Maruko I; Iida T; Sugano Y; Ojima A; Sekiryu T Retina; 2011 Sep; 31(8):1603-8. PubMed ID: 21487334 [TBL] [Abstract][Full Text] [Related]
52. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy. Okamoto M; Matsuura T; Ogata N Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):25-32. PubMed ID: 25559505 [TBL] [Abstract][Full Text] [Related]
53. CHOROIDAL THICKNESS CHANGES IN A PATIENT DIAGNOSED WITH CENTRAL SEROUS CHORIORETINOPATHY DURING FOLLOW-UP FOR PACHYCHOROID PIGMENT EPITHELIOPATHY. Saito W; Hashimoto Y; Hirooka K; Ishida S Retin Cases Brief Rep; 2021 Jan; 15(1):10-14. PubMed ID: 29470299 [TBL] [Abstract][Full Text] [Related]
54. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report. Venkatesh R; Pereira A; Jain K; Yadav NK BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484 [TBL] [Abstract][Full Text] [Related]
55. Comparison of macular choroidal thickness in adult onset foveomacular vitelliform dystrophy and age-related macular degeneration. Coscas F; Puche N; Coscas G; Srour M; Français C; Glacet-Bernard A; Querques G; Souied EH Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):64-9. PubMed ID: 24282233 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of the choroidal features in pachychoroid spectrum diseases by optical coherence tomography and optical coherence tomography angiography. Demirel S; Değirmenci MFK; Batıoğlu F; Özmert E Eur J Ophthalmol; 2021 Jan; 31(1):184-193. PubMed ID: 31684767 [TBL] [Abstract][Full Text] [Related]
57. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858 [TBL] [Abstract][Full Text] [Related]
58. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment. Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913 [TBL] [Abstract][Full Text] [Related]
59. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630 [TBL] [Abstract][Full Text] [Related]
60. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Pryds A; Larsen M Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]